GPX7

Chr 1

glutathione peroxidase 7

NCBI Gene: 2882ENSG00000116157UniProt: Q96SL4

It protects esophageal epithelia from hydrogen peroxide-induced oxidative stress. It suppresses acidic bile acid-induced reactive oxygen species (ROS) and protects against oxidative DNA damage and double-strand breaks

Primary Disease Associations & Inheritance

UniProtBarrett esophagus
29
ClinVar variants
8
Pathogenic / LP
0.00
pLI score
1
Active trials
Clinical Summary— GPX7
⚡
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
8 Pathogenic / Likely Pathogenic· 19 VUS of 29 total submissions
💊
Clinical Trials
1 active or recruiting trial — potential therapeutic options may be available
Some data sources returned errors (2)

clinvar: Error: NCBI fetch failed: 429 https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.41LOEUF
pLI 0.000
Z-score 0.58
OE 0.81 (0.49–1.41)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.18Z-score
OE missense 0.95 (0.80–1.12)
96 obs / 101.2 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.81 (0.49–1.41)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.95 (0.80–1.12)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.84
0≤1.21.6
LoF obs/exp: 9 / 11.1Missense obs/exp: 96 / 101.2Syn Z: 0.84

ClinVar Variant Classifications

29 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic6
Likely Pathogenic2
VUS19
Likely Benign2
6
Pathogenic
2
Likely Pathogenic
19
VUS
2
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
6
0
6
Likely Pathogenic
0
0
2
0
2
VUS
0
17
2
0
19
Likely Benign
0
1
1
0
2
Benign
0
0
0
0
0
Total01811029

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

GPX7 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype

OMIM

No OMIM entries found.

Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.
Rashid MH·MAbs
2022Review
Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
Zhuang Y et al.·J Mol Neurosci
2024
[Expression of Glutathione Peroxidases and Its Effect on Clinical Prognosis in Glioma Patients].
Ren XM et al.·Zhongguo Yi Xue Ke Xue Yuan Xue Bao
2022Cohort
A web-based calculator for predicting the prognosis of patients with sarcoma on the basis of antioxidant gene signatures.
Quan K et al.·Aging (Albany NY)
2022Cohort
Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
Thomaier L et al.·Gynecol Oncol
2021
ISG15 deficiency features a complex cellular phenotype that responds to treatment with itaconate and derivatives.
Waqas SF et al.·Clin Transl Med
2022
Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers.
Kim JC et al.·J Cancer Res Clin Oncol
2011
Glutathione peroxidase family and survival prognosis in patients with renal cell carcinoma.
Li J et al.·Zhong Nan Da Xue Xue Bao Yi Xue Ban
2022Cohort
A pathway-guided strategy identifies a metabolic signature for prognosis prediction and precision therapy for hepatocellular carcinoma.
Shi Q et al.·Comput Biol Med
2022
Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.
Li Y et al.·Clin Cancer Res
2011
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Blue honeysuckle (Lonicera caerulea L.)-anthocyanins and cyanidin-3-O-glucoside protect dopaminergic neurons against ferroptosis by activating the Nrf2-GPX7 axis.
Li XN et al.·Free Radic Biol Med
2025
Multi-Omics and Experimental Validation Identify GPX7 and Glutathione-Associated Oxidative Stress as Potential Biomarkers in Ischemic Stroke.
Li T et al.·Antioxidants (Basel)
2025🔓 Open Access
Metformin's mechanism in reducing oxidative stress and promoting bone regeneration in T2DM rat BMMSCs: A focus on NRF2-GPX7 signaling pathway.
Dong K et al.·J Dent
2025Functional
Co-Exposure to Different Zinc Concentrations and High-Fat Diet Modules Endoplasmic Reticulum Stress and Lipotoxicity through the MTF-1/GPx7 Axis in Yellow Catfish (Pelteobagrus fulvidraco).
Xiao F et al.·J Agric Food Chem
2025
Computational Mutagenesis of GPx7 and GPx8: Structural and Stability Insights into Rare Genetic and Somatic Missense Mutations and Their Implications for Cancer Development.
Sobitan A et al.·Cancers (Basel)
2024🔓 Open Access
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov
Breast Cancer

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

ACTIVE NOT RECRUITING
NCT00616967Phase PHASE2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsStarted 2008-05
carboplatinpaclitaxel albumin-stabilized nanoparticle formulationvorinostat

External Resources

Links to major genomics databases and tools